


USB005

Ophthalmic Solution for the Treatment of Corneal Injury

Principal Investigator: Gere diZerega, M.D., US Biotest, Inc.

- Eye injury and visual dysfunction resulting from battlefield trauma affect a large number of Service members and Veterans
- USB005 Ophthalmic Solution is aseptically formulated for topical ophthalmic administration
- The clear and colorless drug product is contained in sterile 10-g OSD units for preservative-free, multi-use administration
- Treatment with USB005 following corneal incision resulted in normalized tissue architecture and corneal thickness when compared to placebo-control; statistically significant differences ($p < 0.05$) in mean corneal thickness were noted when comparing USB005 to placebo-control; treatment with USB005 after abrasion injury accelerated corneal healing on Day 2
- USB005 is deemed safe in a Phase I clinical trial conducted in 32 healthy volunteers¹




Ophthalmic Squeeze Dispenser

¹ <https://clinicaltrials.gov/ct2/show/NCT03615196>

“Corneal lacerations constitute a large percentage of military ocular trauma cases. USB005 Ophthalmic solution will accelerate wound healing, decrease significant optical discomfort, and shorten the time to return to duty of military personnel.”

***Natalya (Natasha) Merezhinskaya, PhD, Health Research Scientist,
Defense Health Agency J-9 Directorate, Walter Reed National
Military Medical Center, Vision Center of Excellence (VCE)***

Target Commercial Indications



Additional opportunities exist to treat persistent corneal epithelial defects, corneal ulcers, glaucoma, and post photorefractive keratectomy surgery

Congressionally Directed Medical Research Programs



<https://cdmrp.army.mil/vrp/>

Point of Contact: CDMRP Public Affairs, 301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

